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Scientific comment
Comment on “Outcomes of autologous transplantation 
for multiple myeloma according to different induction 
regimens”
Javier de la Rubiaa,b,*
a University Hospital La Fe, Valencia, Spain 
b Universidad Católica de Valencia “San Vicente Mártir”, Valencia, Spain
Treatment of multiple myeloma (MM) has changed significantly 
in the past decade as a result of better understanding of 
disease biology, more effective treatments, and improved 
supportive care. Autologous stem cell transplantation (ASCT) 
is an effective treatment for myeloma and remains a critical 
component for its management. The goal of initial therapy 
remains the same, rapid disease control, and the introduction of 
new drugs such as thalidomide, bortezomib, and lenalidomide 
has enabled us to achieve this goal; combinations of these 
drugs have also led to unprecedented depth of response. On 
the other hand, the availability of these new drugs has given 
way to numerous double, triple, and quadruple combinations; 
nevertheless there is a striking paucity of randomized data 
to enable physicians to choose the best treatment for initial 
therapy. Moreover, most available randomized trials are 
comparisons of newer treatments against older alkylator- 
or anthracycline-based treatments. Thus, in the absence of 
randomized studies comparing different induction regimens, 
it is difficult to recommend one induction treatment over 
another.
Thalidomide is active in MM and produces little hematologic 
toxicity, indicating that it may be preferred for use as 
induction therapy. Several studies evaluating thalidomide, as a 
component of induction therapy, have shown that it improves 
response rates1-8 and progression-free survival (PFS)2,3,5,6,9 
and provides similar5,6,9 or improved overall survival (OS) 
rates versus non-thalidomide containing treatment.3 The 
demonstrated efficacy, lack of myelosuppression, and overall 
tolerability of thalidomide provide a strong reason for its 
incorporation in standard induction treatment in patients 
with newly diagnosed MM who may be eligible for ASCT. In the 
last issue of the Revista Brasileira de Hematologia e Hemoterapia, 
the article of Crusoe et al. show the results of a retrospective 
study comparing pre-transplant induction therapy with 
conventional chemotherapy (VAD) versus thalidomide and 
dexamethasone (TD) or TD plus cyclophosphamide (CTD) in 
152 patients with newly diagnosed MM undergoing front-line 
ASCT (Table 1).10 Although no differences in OS or PFS were 
found between the three groups, the rate of very good partial 
response or better response, both before and after ASCT, 
was higher with treatments that included thalidomide. The 
retrospective design of the study, the fact that only patients 
with at least partial response were included, and the small 
number of patients in each group can help explain the absence 
of significant differences in the follow-up. However, in the 
context of emerging data from ongoing trials using bortezomib 
and lenalidomide combinations, the improvement obtained 
with CTD may just not be the best that can be obtained with 
current therapy. Large, randomized trials are currently under 
way to address this and other clinically relevant questions 
in myeloma therapy today. Despite these limitations, until 
additional randomized data is available, the choice for initial 
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therapy is often driven by opinion and, more importantly, by 
local social or economic boundaries, circumstances that have 
been clearly pointed out by the authors of this paper. 
In summary, the results of this study clearly confirm 
the superiority of thalidomide-based treatments versus 
conventional chemotherapy for the frontline treatment of MM 
patients, and strongly support the use of thalidomide as part 
of the induction regimen in MM patients eligible for ASCT.
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100 60 30-40
TD: thalidomide and dexamethasone.
Table 1 - Results of different induction treatments for 
newly diagnosed multiple myeloma patients eligible for 
transplantation.
